GSK and Ionis won early U.S. approval for bepirovirsen (branded Hibsago), a chronic hepatitis B drug designed for a potential functional cure. The FDA action lands ahead of the companies’ broader commercialization timeline and strengthens the next wave of finite-therapy strategies in HBV. The approval is especially notable because it reframes the competitive landscape toward approaches that aim to reduce long-term dependence on continuous suppression. GSK positions the program as part of its larger growth plan, with bepirovirsen intended to support major revenue targets beyond the near term. For clinicians and payers, the key immediate question will be how the new label translates into real-world uptake—particularly around patient selection and monitoring requirements tied to functional-cure endpoints.